Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 10
Submit an article Journal homepage
714
Views
19
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Incidence, etiology and timing of infections following azacitidine therapy for myelodysplastic syndromes

Jason A. TrubianoDepartment of Infectious Diseases, Peter MacCallum Cancer Centre, East Melbourne, Australia; ;Department of Medicine, University of Melbourne, Melbourne, Australia; Correspondence[email protected]
View further author information
,
Michael DickinsonDepartment of Haematology, Peter MacCallum Cancer Centre, East Melbourne, Australia; View further author information
,
Karin A. ThurskyDepartment of Infectious Diseases, Peter MacCallum Cancer Centre, East Melbourne, Australia; ;Department of Medicine, University of Melbourne, Melbourne, Australia; ;Victorian Infectious Diseases Service, Royal Melbourne Hospital at the Peter Doherty Institute, Melbourne, AustraliaView further author information
,
Timothy SpelmanDepartment of Medicine, University of Melbourne, Melbourne, Australia; View further author information
,
John F. SeymourDepartment of Medicine, University of Melbourne, Melbourne, Australia; ;Department of Haematology, Peter MacCallum Cancer Centre, East Melbourne, Australia; View further author information
,
Monica A. SlavinDepartment of Infectious Diseases, Peter MacCallum Cancer Centre, East Melbourne, Australia; ;Department of Medicine, University of Melbourne, Melbourne, Australia; ;Victorian Infectious Diseases Service, Royal Melbourne Hospital at the Peter Doherty Institute, Melbourne, AustraliaView further author information
&
Leon J. WorthDepartment of Infectious Diseases, Peter MacCallum Cancer Centre, East Melbourne, Australia; ;Department of Medicine, University of Melbourne, Melbourne, Australia; View further author information
 show all
Pages 2379-2386 | Received 19 Jul 2016, Accepted 04 Feb 2017, Published online: 28 Feb 2017

Citations (19)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Alessandro Busca & Livio Pagano. (2018) Prophylaxis for aspergillosis in patients with haematological malignancies: pros and cons. Expert Review of Anti-infective Therapy 16:7, pages 531-542.
Read now

Articles from other publishers (18)

Mariana Guarana & Marcio Nucci. (2023) Should patients with acute myeloid leukemia treated with venetoclax-based regimens receive antifungal prophylaxis?. Leukemia Research 131, pages 107341.
Crossref
Tugcan Alp Kirkizlar, Onur Kirkizlar, Ufuk Demirci, Aytug Umut, Huseyin Iflazoglu, Elif Gulsum Umit & Ahmet Muzaffer Demir. (2023) Incidence and predisposing factors of infection in patients treated with hypomethylating agents. Leukemia Research 127, pages 107043.
Crossref
Mary M Czech, Maria Veronica Dioverti, Andrew H Karaba, Tania Jain, Sai M Talluru, Joel C Sunshine, Jun Kang, Nikki Parrish & Olivia S Kates. (2022) Disseminated Tuberculosis With an Atypical Cutaneous Manifestation in a Hematopoietic Cell Transplant Patient in the Early Posttransplant Period: Case Report and Review of the Literature. Open Forum Infectious Diseases 9:12.
Crossref
Sing-Ting Wang, Chia-Huei Chou, Tzu-Ting Chen, Ching-Chan Lin, Li-Yuan Bai, Shih-Peng Yeh, Mao-Wang Ho & Ming-Yu Lien. (2022) High rate of invasive fungal infections during early cycles of azacitidine for patients with acute myeloid leukemia. Frontiers in Cellular and Infection Microbiology 12.
Crossref
Lorenza Bellusci, Gabrielle Grubbs, Pragya SrivastavaMichael J. Nemeth, Elizabeth A. Griffiths, Hana Golding & Surender Khurana. (2022) Neutralization of SARS-CoV-2 Omicron after vaccination of patients with myelodysplastic syndromes or acute myeloid leukemia. Blood 139:18, pages 2842-2846.
Crossref
Jannik Stemler, Nick de Jonge, Nicole Skoetz, János Sinkó, Roger J Brüggemann, Alessandro Busca, Ronen Ben-Ami, Zdeněk Ráčil, Vanessa Piechotta, Russell Lewis & Oliver A Cornely. (2022) Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association. The Lancet Haematology 9:5, pages e361-e373.
Crossref
Amanda Tey, Briony Shaw, Luke Cardamone, Sam Shepherd, Eldho Paul, Ben Rogers & Jake Shortt. (2021) Risk factors for invasive fungal infection in 5‐azacytidine treated patients with acute myeloid leukemia and myelodysplastic syndrome. European Journal of Haematology 107:2, pages 181-189.
Crossref
Gee Youn (Geeny) Kim, Jonathan Burns, Craig W. Freyer, Keith W. Hamilton, Noelle V. Frey, Saar I. Gill, Elizabeth O. Hexner, Selina M. Luger, James K. Mangan, Mary E. Martin, Shannon R. McCurdy, Alexander E. Perl, David L. Porter, Mindy G. Schuster, Edward A. Stadtmauer & Alison W. Loren. (2020) Risk of invasive fungal infections in patients with high‐risk MDS and AML receiving hypomethylating agents . American Journal of Hematology 95:7, pages 792-798.
Crossref
Roberto Latagliata, Pasquale Niscola, Luana Fianchi, Maria Antonietta Aloe Spiriti, Luca Maurillo, Ida Carmosino, Laura Cesini, Chiara Sarlo, Annalina Piccioni, Alessia Campagna, Maria Lucia De Luca, Daniela De Benedittis, Marco Mancini, Massimo Breccia, Marianna Criscuolo, Francesco Buccisano, Maria Teresa Voso, Giuseppe Avvisati, Agostino Tafuri, Paolo De Fabritiis, Robin Foà & Corrado Girmenia. (2020) Pulmonary infections in patients with myelodysplastic syndromes receiving frontline azacytidine treatment. Hematological Oncology 38:2, pages 189-196.
Crossref
Ka-Won Kang, Byung-Hyun Lee, Min Ji Jeon, Eun Sang Yu, Dae Sik Kim, Se Ryeon Lee, Hwa Jung Sung, Chul Won Choi, Yong Park & Byung Soo Kim. (2020) Efficacy of posaconazole prophylaxis in acute myeloid leukemia and myelodysplastic syndrome patients treated with hypomethylating agents. Therapeutic Advances in Hematology 11, pages 204062072096688.
Crossref
Grzegorz Helbig, Karolina Chromik, Krzysztof Woźniczka, Anna J. Kopińska, Kinga Boral, Martyna Dworaczek, Anna Koclęga, Anna Armatys, Marta Panz-Klapuch & Mirosław Markiewicz. (2019) Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia. Pathology & Oncology Research 25:3, pages 1175-1180.
Crossref
Krzysztof Mądry, Karol Lis, Przemysław Biecek, Magda Młynarczyk, Jagoda Rytel, Michał Górka, Piotr Kacprzyk, Magdalena Dutka, Marek Rodzaj, Łukasz Bołkun, Dorota Krochmalczyk, Ewa Łątka, Joanna Drozd-Sokołowska, Anna Waszczuk-Gajda, Wanda Knopińska-Posłuszny, Anna Kopińska, Edyta Subocz, Anna Masternak, Renata Guzicka-Kazimierczak, Lidia Gil, Rafał Machowicz, Jarosław Biliński, Sebastian Giebel, Tomasz Czerw & Jadwiga Dwilewicz-Trojaczek. (2019) Predictive Model for Infection Risk in Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Patients Treated With Azacitidine; Azacitidine Infection Risk Model: The Polish Adult Leukemia Group Study. Clinical Lymphoma Myeloma and Leukemia 19:5, pages 264-274.e4.
Crossref
Corrado Girmenia, Anna Candoni, Mario Delia, Roberto Latagliata, Alfredo Molteni, Esther N. Oliva, Giuseppe A. Palumbo, Antonella Poloni, Prassede Salutari, Valeria Santini, Maria Teresa Voso & Pellegrino Musto. (2019) Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations. Blood Reviews 34, pages 16-25.
Crossref
Marta Stanzani & Russell Lewis. (2018) Development and Applications of Prognostic Risk Models in the Management of Invasive Mold Disease. Journal of Fungi 4:4, pages 141.
Crossref
Liat Shargian-Alon, Ronit Gurion, Pia Raanani, Dafna Yahav & Anat Gafter-Gvili. (2018) Hypomethylating Agents-associated Infections—Systematic Review and Meta-analysis of Randomized Controlled Trials. Clinical Lymphoma Myeloma and Leukemia 18:9, pages 603-610.e1.
Crossref
David J Epstein, Susan K Seo, Janice M Brown & Genovefa A Papanicolaou. (2018) Echinocandin prophylaxis in patients undergoing haematopoietic cell transplantation and other treatments for haematological malignancies. Journal of Antimicrobial Chemotherapy 73:suppl_1, pages i60-i72.
Crossref
Myrna Candelaria, Sebastian Burgos, Mayra Ponce, Ramiro Espinoza & Alfonso Dueñas-Gonzalez. (2017) Encouraging results with the compassionate use of hydralazine/valproate (TRANSKRIP™) as epigenetic treatment for myelodysplastic syndrome (MDS). Annals of Hematology 96:11, pages 1825-1832.
Crossref
. (2017) Azacitidine. Reactions Weekly 1667:1, pages 53-53.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.